COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Nabilone & Marijuana Addiction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01025700
Recruitment Status : Completed
First Posted : December 3, 2009
Last Update Posted : February 17, 2011
Information provided by:
University of British Columbia

Brief Summary:
Safety of Nabilone in reducing marijuana craving

Condition or disease Intervention/treatment Phase
Marijuana Smoking Drug: Cesemat Phase 2 Phase 3

Detailed Description:
Randomized double blind trial into the safety and efficacy of Cesemat for the treatment of marijuana use

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 35 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Double-Blind Placebo Control Study on the Use of Nabilone for Outpatient Management of Acute Marijuana Withdrawal
Study Start Date : June 2009
Actual Primary Completion Date : June 2010
Actual Study Completion Date : October 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Marijuana
Drug Information available for: Nabilone

Arm Intervention/treatment
Experimental: Cesemat Drug: Cesemat
1 mg capsule per day for 21 days
Other Name: Nabilone

No Intervention: Placebo

Primary Outcome Measures :
  1. Safety and tolerability to Nabilone

Secondary Outcome Measures :
  1. Marijuana craving questionnaire

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 19 years or older
  • History of marijuana use

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01025700

Layout table for location information
Canada, British Columbia
Vancouver General Hospital - Psychiatry Outpatient
Vancouver, British Columbia, Canada
Sponsors and Collaborators
University of British Columbia
Layout table for investigator information
Principal Investigator: Shaohua Lu, MD University of British Columbia
Layout table for additonal information
Responsible Party: Shaohua Lu, MD, University of British Columbia Identifier: NCT01025700    
Other Study ID Numbers: H08-01999
First Posted: December 3, 2009    Key Record Dates
Last Update Posted: February 17, 2011
Last Verified: February 2011
Keywords provided by University of British Columbia:
Additional relevant MeSH terms:
Layout table for MeSH terms
Marijuana Abuse
Marijuana Use
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs